CAJ | 학술논문

目的：现察左西孟旦对老年慢性心衰失代偿期患者血清中的肿瘤坏死因子( Tumor Necrosis Factor-alpha, TNF-α)和氮基末端B型利钠肽前体(Amino Terminal pro-B-type Natriuretic Peptide Precursor,NT-proBNP)水平的影响.方法慢性心力衰竭患者96例,随机分为2组,46例常规治疗组,50例左西孟旦组,并选同期正常体检者40例为对照组.结果治疗前,两个组别的心脏彩超指标无显著差异(P>0.05),治疗后,两个组别的心脏指标有不同程度的改善(P<0.05),与常规治疗组相比,左西孟旦组的心脏指标改善明显(P<0.05),与对照组相当(P>0.05).与对照组相比,两组慢性心衰病患的TNF-α和NT-proBNP明显增高(P<0.05),治疗前两组慢性心衰病患的TNF-α和NT-proBNP无显著差异(P>0.05),治疗后两组慢性心衰病患的TNF-α和NT-proBNP均明显降低(P<0.05),但与常规治疗组相比,左西孟旦组的TNF-α和NT-proBNP降低明显(P<0.05).与常规治疗组比,左西孟旦组的呼吸困难评分降低明显(P<0.05).两个组别均无明显不良反应.结论左西孟旦对慢性心衰患者预后有较好的改善作用,进一步的机制还需深入研究.
목적：현찰좌서맹단대노년만성심쇠실대상기환자혈청중적종류배사인자( Tumor Necrosis Factor-alpha, TNF-α)화담기말단B형리납태전체(Amino Terminal pro-B-type Natriuretic Peptide Precursor,NT-proBNP)수평적영향.방법만성심력쇠갈환자96례,수궤분위2조,46례상규치료조,50례좌서맹단조,병선동기정상체검자40례위대조조.결과치료전,량개조별적심장채초지표무현저차이(P>0.05),치료후,량개조별적심장지표유불동정도적개선(P<0.05),여상규치료조상비,좌서맹단조적심장지표개선명현(P<0.05),여대조조상당(P>0.05).여대조조상비,량조만성심쇠병환적TNF-α화NT-proBNP명현증고(P<0.05),치료전량조만성심쇠병환적TNF-α화NT-proBNP무현저차이(P>0.05),치료후량조만성심쇠병환적TNF-α화NT-proBNP균명현강저(P<0.05),단여상규치료조상비,좌서맹단조적TNF-α화NT-proBNP강저명현(P<0.05).여상규치료조비,좌서맹단조적호흡곤난평분강저명현(P<0.05).량개조별균무명현불량반응.결론좌서맹단대만성심쇠환자예후유교호적개선작용,진일보적궤제환수심입연구.
Objective To investigate the effect of Levosimendan on TNF-α( Tumor Necrosis Factor-alpha ) and amino terminal proB-type natriuretic peptide(NT-proBNP)of elderly patients with chronic decompensation heart failure. Method 96 cases of elderly chronic decompensation heart failure were randomly divided into 2 groups:46 cases of conventional treatment group and 50 cases of levosimendan group. Meanwhile,40 cases of health patients were collected as the control group. Results Before treatment, there was no significant difference between 2 groups on heart function parameters(P>0. 05). After treatment,heart function of both groups improved (P<0. 05). Compared with the control group,the heart function improved obviously(P<0. 05). Compared with the control group, TNF-α and NT-proBNP of the two groups were significantly higher ( P<0. 05 ). Before treatment,TNF-α and NT-proBNP had no significant differences between the two groups(P>0. 05). After treatment,TNF-α and NT-proBNP of two groups decreased significantly(P<0. 05). Compared to the conventional treatment group, TNF-α and NT-proBNP in the Levosimendan group were significantly lower ( P<0. 05 ). Compared to the comentional treatment group,the dyspnea scores in the Levosimendan group were significantly lower(P<0. 05). Conclusion Levosimendan has positive effect on the prognosis of patients with chronic heart failure,and further mechanism still needs further study.